EP3986377A4 - Formulations parasiticides à base d'isoxazoline et procédés de traitement de blépharite - Google Patents
Formulations parasiticides à base d'isoxazoline et procédés de traitement de blépharite Download PDFInfo
- Publication number
- EP3986377A4 EP3986377A4 EP20826079.4A EP20826079A EP3986377A4 EP 3986377 A4 EP3986377 A4 EP 3986377A4 EP 20826079 A EP20826079 A EP 20826079A EP 3986377 A4 EP3986377 A4 EP 3986377A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- isoxazoline
- methods
- treating blepharitis
- parasiticidal formulations
- parasiticidal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Polymers & Plastics (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dentistry (AREA)
- Birds (AREA)
- Agronomy & Crop Science (AREA)
- Wood Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863822P | 2019-06-19 | 2019-06-19 | |
| US202063029689P | 2020-05-25 | 2020-05-25 | |
| PCT/US2020/038758 WO2020257663A1 (fr) | 2019-06-19 | 2020-06-19 | Formulations parasiticides à base d'isoxazoline et procédés de traitement de blépharite |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3986377A1 EP3986377A1 (fr) | 2022-04-27 |
| EP3986377A4 true EP3986377A4 (fr) | 2023-07-19 |
Family
ID=74040459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20826079.4A Pending EP3986377A4 (fr) | 2019-06-19 | 2020-06-19 | Formulations parasiticides à base d'isoxazoline et procédés de traitement de blépharite |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3986377A4 (fr) |
| JP (2) | JP2022537389A (fr) |
| KR (1) | KR20220053550A (fr) |
| CN (1) | CN114269324A (fr) |
| AU (1) | AU2020295570A1 (fr) |
| BR (1) | BR112021025701A2 (fr) |
| CA (1) | CA3144264A1 (fr) |
| IL (2) | IL289109B2 (fr) |
| MX (1) | MX2021016055A (fr) |
| WO (1) | WO2020257663A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016022066A1 (fr) | 2014-08-04 | 2016-02-11 | Jerry Tan Eye Surgery Pte Ltd | Compositions pharmaceutiques pour blépharite et encroûtement des paupières liés à demodex |
| AU2018385766B2 (en) | 2017-12-15 | 2022-12-01 | Tarsus Pharmaceuticals, Inc. | Isoxazoline parasiticide formulations and methods for treating blepharitis |
| WO2022156371A1 (fr) * | 2021-01-22 | 2022-07-28 | 成都瑞沐生物医药科技有限公司 | Support ou substance auxiliaire de préparation ophtalmique, son procédé de préparation et son application |
| US20220323472A1 (en) * | 2021-03-30 | 2022-10-13 | Frank Anthony SPALLITTA | Anti-parasitic compounds for the treatment and prevention of viral diseases |
| PL4312986T3 (pl) * | 2021-04-01 | 2025-02-17 | Active Biotech Ab | Preparat lakwinimodu do stosowania do oczu |
| WO2024168149A1 (fr) * | 2023-02-10 | 2024-08-15 | Tarsus Pharmaceuticals, Inc. | Formulations parasiticides à base d'isoxazoline et méthodes de traitement de la blépharite |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006119174A1 (fr) * | 2005-04-30 | 2006-11-09 | Ocular Surface Center, P.A. | Methode de traitement oculaire de demodex |
| WO2016022066A1 (fr) * | 2014-08-04 | 2016-02-11 | Jerry Tan Eye Surgery Pte Ltd | Compositions pharmaceutiques pour blépharite et encroûtement des paupières liés à demodex |
| WO2019118928A1 (fr) * | 2017-12-15 | 2019-06-20 | Tarsus Pharmaceuticals, Inc. | Préparations de parasiticides à base d'isoxazoline et méthodes de traitement de la blépharite |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2891460B1 (fr) * | 2005-09-30 | 2010-07-30 | Galderma Sa | Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum. |
| US20090317503A1 (en) * | 2008-06-20 | 2009-12-24 | Ocusoft, Inc. | Eyelid Preparation and Method of Use |
| JP5246182B2 (ja) * | 2010-02-24 | 2013-07-24 | ライオン株式会社 | 点眼剤、防腐剤及び防腐力向上剤 |
| BR112012026364B1 (pt) * | 2010-04-12 | 2018-04-10 | Exosect Limited | Controle de artrópodes em ambientes de animais |
| WO2012107533A1 (fr) * | 2011-02-10 | 2012-08-16 | Novartis Ag | Dérivées d'isoxazoline pour la lutte contre des animaux nuisibles invertébrés |
| RU2688919C1 (ru) * | 2013-12-20 | 2019-05-23 | Интервет Интернэшнл Б.В. | Изоксазолиновые композиции и их применение в провилактике или лечении паразитарных инвазий животных |
| JP7569781B2 (ja) * | 2018-07-27 | 2024-10-18 | アペルタ バイオサイエンシズ,エルエルシー | デモデックスにより誘発される眼の異常および顔面の異常を治療するためのスピノシン配合 |
-
2020
- 2020-06-19 IL IL289109A patent/IL289109B2/en unknown
- 2020-06-19 CN CN202080050179.5A patent/CN114269324A/zh active Pending
- 2020-06-19 JP JP2021575891A patent/JP2022537389A/ja active Pending
- 2020-06-19 CA CA3144264A patent/CA3144264A1/fr active Pending
- 2020-06-19 EP EP20826079.4A patent/EP3986377A4/fr active Pending
- 2020-06-19 IL IL321061A patent/IL321061A/en unknown
- 2020-06-19 KR KR1020227001984A patent/KR20220053550A/ko active Pending
- 2020-06-19 WO PCT/US2020/038758 patent/WO2020257663A1/fr not_active Ceased
- 2020-06-19 MX MX2021016055A patent/MX2021016055A/es unknown
- 2020-06-19 AU AU2020295570A patent/AU2020295570A1/en active Pending
- 2020-06-19 BR BR112021025701A patent/BR112021025701A2/pt unknown
-
2025
- 2025-07-10 JP JP2025116873A patent/JP2025137609A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006119174A1 (fr) * | 2005-04-30 | 2006-11-09 | Ocular Surface Center, P.A. | Methode de traitement oculaire de demodex |
| WO2016022066A1 (fr) * | 2014-08-04 | 2016-02-11 | Jerry Tan Eye Surgery Pte Ltd | Compositions pharmaceutiques pour blépharite et encroûtement des paupières liés à demodex |
| WO2019118928A1 (fr) * | 2017-12-15 | 2019-06-20 | Tarsus Pharmaceuticals, Inc. | Préparations de parasiticides à base d'isoxazoline et méthodes de traitement de la blépharite |
Non-Patent Citations (3)
| Title |
|---|
| JOHN THOMAS: "The preservative question", OPHTHALMOLOGY MANAGEMENT -, 1 August 2012 (2012-08-01), XP093052673, Retrieved from the Internet <URL:https://www.ophthalmologymanagement.com/issues/2012/august-2012/corneal-clarity> [retrieved on 20230607] * |
| QUIROZ-MERCADO HUGO ET AL: "Pilot Study to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Blepharitis Due to Demodex Infestation (Mars Study)", vol. 21, no. 7, 1 June 2020 (2020-06-01), pages 2984, XP093052443, Retrieved from the Internet <URL:https://iovs.arvojournals.org/article.aspx?articleid=2767821> * |
| See also references of WO2020257663A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3144264A1 (fr) | 2020-12-24 |
| CN114269324A (zh) | 2022-04-01 |
| IL289109A (en) | 2022-02-01 |
| IL289109B2 (en) | 2025-10-01 |
| EP3986377A1 (fr) | 2022-04-27 |
| WO2020257663A1 (fr) | 2020-12-24 |
| IL321061A (en) | 2025-07-01 |
| JP2025137609A (ja) | 2025-09-19 |
| KR20220053550A (ko) | 2022-04-29 |
| BR112021025701A2 (pt) | 2022-03-03 |
| JP2022537389A (ja) | 2022-08-25 |
| IL289109B1 (en) | 2025-06-01 |
| MX2021016055A (es) | 2022-04-20 |
| AU2020295570A1 (en) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3986377A4 (fr) | Formulations parasiticides à base d'isoxazoline et procédés de traitement de blépharite | |
| EP3723739A4 (fr) | Préparations de parasiticides à base d'isoxazoline et méthodes de traitement de la blépharite | |
| MA45290A (fr) | Procédés et compositions d'agents biologiquement actifs | |
| EP3781214A4 (fr) | Compositions et procédés de traitement de l'amyotrophie spinale | |
| EP3681513A4 (fr) | Agents d'arni et compositions destinées à inhiber l'expression d'analogue de l'angiopoïétine 3 (angptl3) et procédés d'utilisation | |
| EP3647311A4 (fr) | Inhibiteur de protéine kinase associée à rho, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation | |
| MA49045A (fr) | Compositions et procédés destinés à la distribution régulée d'acide | |
| MA42819A (fr) | Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae | |
| EP3458585A4 (fr) | Procédés de thérapie génique pour des maladies et des affections liées à l'âge | |
| EP3377042A4 (fr) | Substances et procédés de traitement de myopathies à base de titine et d'autres titinopathies | |
| MA53558A (fr) | Compositions et procédés pour le traitement d'infections virales | |
| EP3545106A4 (fr) | Procédés d'enrichissement et de détermination de séquences nucléotidiques cibles | |
| EP3310395A4 (fr) | Régulation de la transcription à guidage arn et procédés d'utilisation de celle-ci pour le traitement des lombalgies | |
| EP3833340A4 (fr) | Compositions et procédés de traitement de la presbytie | |
| EP3452578A4 (fr) | Procédés de fabrication in vitro de tissu de fundus d'estomac et compositions associées à celui-ci | |
| EP3592841A4 (fr) | Procédés et compositions de traitement de cancers à l'aide d'acides nucléiques antisens | |
| EP3761784A4 (fr) | Nouveaux procédés d'élevage et libération régulée d'agents de lutte biologique | |
| EP3740463A4 (fr) | Composition d'oligoéléments à sources multiples et procédés de traitement du sol à l'aide de celle-ci | |
| EP4013474A4 (fr) | Injecteurs de micro-volume à guidage de dose et procédés d'utilisation | |
| EP4255405A4 (fr) | Procédés et compositions pour des agents thérapeutiques à base de cannabinoïdes | |
| EP3523281A4 (fr) | Activateurs de flux autophagique et de phospholipase d et clairance d'agrégats de protéines comprenant tau et traitement de protéinopathies | |
| EP3843524A4 (fr) | Composition de traitement des semences et procédé d'utilisation | |
| EP3723733A4 (fr) | Méthodes et compositions pour le traitement du cancer utilisant des exosomes associés à l'édition génique | |
| EP3413904A4 (fr) | Compositions à base de plantes et procédés de prévention et de traitement d'infections de plantes ou d'infections unguéales | |
| EP3833533A4 (fr) | Fabrication d'additif non orthogonal et traitement de pièces fabriquées à partir de celui-ci |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20220107 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0009000000 Ipc: A61K0031420000 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20230619 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A01N 43/80 20060101ALI20230613BHEP Ipc: A01N 25/02 20060101ALI20230613BHEP Ipc: A23K 20/105 20160101ALI20230613BHEP Ipc: A61K 47/14 20170101ALI20230613BHEP Ipc: A61K 47/26 20060101ALI20230613BHEP Ipc: A61K 47/10 20170101ALI20230613BHEP Ipc: A61P 27/02 20060101ALI20230613BHEP Ipc: A61K 9/00 20060101ALI20230613BHEP Ipc: A61K 31/422 20060101ALI20230613BHEP Ipc: A61K 31/42 20060101AFI20230613BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20250624 |